These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21511807)

  • 1. The risk of deep venous thrombosis with oral contraceptives containing drospirenone.
    Dunn N
    BMJ; 2011 Apr; 342():d2519. PubMed ID: 21511807
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
    Sehovic N; Smith KP
    Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
    Dinger JC; Heinemann LA; Kühl-Habich D
    Contraception; 2007 May; 75(5):344-54. PubMed ID: 17434015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone and VTE.
    Leppée M; Eric M; Culig J
    J Fam Plann Reprod Health Care; 2010 Jan; 36(1):44. PubMed ID: 20067674
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
    Jick SS; Hernandez RK
    BMJ; 2011 Apr; 342():d2151. PubMed ID: 21511805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.
    Raymond EG; Burke AE; Espey E
    Obstet Gynecol; 2012 May; 119(5):1039-44. PubMed ID: 22525916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drospirenone: high risk of venous thrombosis.
    Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
    Parkin L; Sharples K; Hernandez RK; Jick SS
    BMJ; 2011 Apr; 342():d2139. PubMed ID: 21511804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yasmin--an oral contraceptive with a new progestin.
    Med Lett Drugs Ther; 2002 Jun; 44(1133):55-7. PubMed ID: 12080274
    [No Abstract]   [Full Text] [Related]  

  • 11. Drospirenone-related venous thromboembolism risk: "the rest of the story".
    Casey PM; Files JA; Mayer AP
    J Womens Health (Larchmt); 2013 May; 22(5):467-8. PubMed ID: 23659485
    [No Abstract]   [Full Text] [Related]  

  • 12. Drospirenone Litigation: Does the Punishment Fit the Crime?
    Batur P; Casey PM
    J Womens Health (Larchmt); 2017 Feb; 26(2):99-102. PubMed ID: 27854556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral hormonal contraception and venous thromboembolism (VTE).
    Reid RL
    Contraception; 2014 Apr; 89(4):235-6. PubMed ID: 24594431
    [No Abstract]   [Full Text] [Related]  

  • 14. Yasmin and venous thromboembolism: new case reports.
    López M; Vayá A; Martínez Triguero ML; Contreras MT; Todolí J; Ricart A; Laiz B
    Clin Hemorheol Microcirc; 2009; 42(1):65-9. PubMed ID: 19363241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drospirenone: venous thrombosis (continued).
    Prescrire Int; 2012 Feb; 21(124):43. PubMed ID: 22413722
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of venous thromboembolism with drospirenone-containing oral contraceptives.
    Brown DA; Vartan CM
    Am J Health Syst Pharm; 2011 Jun; 68(11):1003-10. PubMed ID: 21593228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
    Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism is egregiously underestimated.
    Shapiro S
    BMJ; 2011 May; 342():d3344. PubMed ID: 21628367
    [No Abstract]   [Full Text] [Related]  

  • 19. Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
    Tartarone A; Gallucci G; Cammarota A; Romano G; Ardito R; Di Renzo N
    Bone Marrow Transplant; 2005 Jan; 35(1):103. PubMed ID: 15531905
    [No Abstract]   [Full Text] [Related]  

  • 20. Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters.
    Larivée N; Suissa S; Coulombe J; Tagalakis V; Filion KB
    Drug Saf; 2017 Jul; 40(7):583-596. PubMed ID: 28382493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.